← Back to Search

sumatriptan nasal powder for Migraine

Phase 3
Waitlist Available
Research Sponsored by Currax Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 120 minutes
Awards & highlights

Study Summary

This trial will test if sumatriptan nasal powder is safe and effective in treating migraines in adolescents aged 12-17.

Eligible Conditions
  • Migraine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~120 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 120 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Were Headache Pain Free at 120 Minutes After Treatment
Secondary outcome measures
Change from Baseline in headache severity any time after treatment
Mean time to rescue medication use
Number of participants using rescue medication
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Sumatriptan nasal powderExperimental Treatment1 Intervention
Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
Group II: PlaceboPlacebo Group1 Intervention
Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.

Find a Location

Who is running the clinical trial?

Currax PharmaceuticalsLead Sponsor
6 Previous Clinical Trials
76,794 Total Patients Enrolled
Michael Kyle, MDStudy ChairCurrax Pharmaceuticals
1 Previous Clinical Trials
486 Total Patients Enrolled
Errol Gould, PhDStudy ChairCurrax Pharmaceuticals

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Oklahoma
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
2017. "Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03338920.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top